Context-dependent value of HLA class I diversity in advanced non-small cell lung cancer treated with immune checkpoint blockade
BackgroundImmune checkpoint inhibitors (ICI), alone or in combination with chemotherapy, are the standard first-line treatment for advanced non–small cell lung cancer (NSCLC) without actionable oncogenic drivers. Programmed death-ligand 1 (PD-L1) expre…